Characterization of hard‐to‐differentiate dune stratification types in the Permian Coconino Sandstone (Arizona, USA)

Dune stratification types, which include grainfall, grainflow and ripple lamination, provide a record of the fine‐scale processes that deposited sediment on palaeo‐dune foresets. While these facies are relatively easy to distinguish in some cross‐bedded sandstones, for others – like the Permian Coconino Sandstone of northern and central Arizona – discrete stratification styles are hard to recognize at the bedding scale. Furthermore, few attempts have been made to classify fine‐scale processes in this sandstone, despite its renown as a classic aeolian dune deposit and Grand Canyon formation. To interpret depositional processes in the Coconino Sandstone, cross‐bed facies were characterized using a suite of sedimentary textures and structures. Bedding parameters were described at multiple scales via a combination of field and laboratory methods, including annotated outcrop photomosaics, strike and dip measurements, sandstone disaggregation and laser‐diffraction particle analysis, high‐resolution scans of thin sections, and scanning electron microscopy. Cross‐beds were observed to be laterally extensive along‐strike, with most dip angles ranging from the mid‐teens to mid‐twenties. While some cross‐bed sets are statistically coarser near their bases, others exhibit no significant vertical sorting trends. Both massive and laminated textures are visible in high‐resolution scans of thin sections, but laminae contacts are commonly indistinct, making normal and reverse grading difficult to define. Diagenetic features, such as stylolite seams and large pores, are also present in some samples and might indicate alteration of original textures like detrital clay laminae and carbonate minerals. Observed textures and sedimentary structures suggest that the cross‐beds may consist of grainflow and grainfall deposits, but these remain difficult to differentiate at outcrop and thin‐section scales. This characterization of fine‐scale processes will play a critical part in the development of depositional models for the Coconino Sandstone and elucidate interpretations for similar cross‐bedded formations

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate. METHODS: CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death; their relative safety was also assessed. The population studied comprised subgroups of patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease. Patients were followed for 1 to 3 years. FINDINGS: 19,185 patients, with more than 6300 in each of the clinical subgroups, were recruited over 3 years, with a mean follow-up of 1.91 years. There were 1960 first events included in the outcome cluster on which an intention-to-treat analysis showed that patients treated with clopidogrel had an annual 5.32% risk of ischaemic stroke, myocardial infarction, or vascular death compared with 5.83% with aspirin. These rates reflect a statistically significant (p = 0.043) relative-risk reduction of 8.7% in favour of clopidogrel (95% Cl 0.3-16.5). Corresponding on-treatment analysis yielded a relative-risk reduction of 9.4%. There were no major differences in terms of safety. Reported adverse experiences in the clopidogrel and aspirin groups judged to be severe included rash (0.26% vs 0.10%), diarrhoea (0.23% vs 0.11%), upper gastrointestinal discomfort (0.97% vs 1.22%), intracranial haemorrhage (0.33% vs 0.47%), and gastrointestinal haemorrhage (0.52% vs 0.72%), respectively. There were ten (0.10%) patients in the clopidogrel group with significant reductions in neutrophils (< 1.2 x 10(9)/L) and 16 (0.17%) in the aspirin group. INTERPRETATION: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death. The overall safety profile of clopidogrel is at least as good as that of medium-dose aspirin